[…]
“I’m a big believer that prevention is the best type of cure. So, for ductal carcinoma in situ (DCIS), also known as stage zero breast cancer, we have a window of opportunity to be proactive before it becomes an invasive cancer. My philosophy is to personalize the treatment so that we are treating the right women and not treating the right women. I don’t want to subject someone to radiotherapy treatment if there’s no benefit for their particular tumor.”
In this webinar, Dr. Pat Whitworth, MD, FACS, Chirag Shah, MD, and Troy Bremer, PhD, provide an overview of recently published data in the Red Journal of PreludeDx’s #DCISionRT and its newly integrated Residual Risk Subtype (RRt).
“My Decision Score was a 9.2 out of 10, which is quite high. The test showed that my total risk (DCIS + invasive) of recurrence over the next 10 years was 42% without radiation and 15% with radiation. So, I am very happy that I am doing the right thing. And my doctor was impressed with the test and will be using it for other patients.”
“I went in for my yearly physical and never thought for a second that anything would be wrong. I’m not a typical candidate for breast cancer nor do I have breast cancer anywhere in my family history. After my mammogram, I received a call that something was suspicious, and they wanted me to come in for an ultrasound. I had a biopsy and received a diagnosis of DCIS.”
“Without DCISionRT, I would have most likely received full radiation since my tumor pathology was considered medium (intermediate) to high grade. So, DCISionRT allowed me to make a health decision that I wouldn’t have otherwise been able to confidently make. Without DCISionRT I would have been throwing darts in the dark – do I need full radiation, partial radiation or no radiation?”
“My advice for other DCIS patients is to do your research and be your own advocate. Trust your instincts. If you don’t have a good feeling, you may need to push for additional testing or a 2nd opinion. And it’s not easy to challenge your doctor. But that’s what you must do until you feel comfortable.”
Troy Bremer, PhD, founder and CSO of PreludeDx, and Rachel Rabinovitch, MD, FASTRO, Professor of Radiation Oncology at University of Colorado, discuss DCISionRT and how it is used in the real-world clinical setting and the resulting changes in practice of precision medicine.
“In practice, I think there is a fine line between overtreating and undertreating breast cancer patients, and DCIS is squarely in that gray zone. Prior to DCISionRT, all DCIS patients got radiation. As an academic institution, we value and pride ourselves on following evidence-based literature and recommendations. DCISionRT is backed by strong evidence. That makes it easy to incorporate. And it is an important tool to use as a multidisciplinary group to determine if we should recommend radiation or not, because we are finding out that some women don’t actually need radiation.”
Troy Bremer, PhD; Julie Margenthaler, MD, FACS; and Chirag Shah, MD discuss the evaluation and use of DCISionRT in real-world setting, the resulting changes in practice of precision medicine, and the introduction of DCISionRT with novel residual risk subtype.